<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363426</url>
  </required_header>
  <id_info>
    <org_study_id>CP-006</org_study_id>
    <nct_id>NCT02363426</nct_id>
  </id_info>
  <brief_title>Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation</brief_title>
  <official_title>Randomized Controlled Open-Label Non-Inferiority Trial Comparing Day 5 Embryos Derived From Intravaginal Culture Using the Medical Device INVOcell to Traditional In Vitro Fertilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Invaron Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Invaron Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate intravaginal culture using the medical device&#xD;
      INVOcell to generate day 5 blastocysts in comparison to traditional IVF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, single center, open label randomized comparative trial to evaluate&#xD;
      intravaginal culture using INVOcell vs. traditional IVF to generate day 5 embryos Pilot: 40&#xD;
      couples (80 patients), randomized to receive either intravaginal culture (n=20) using the&#xD;
      INVOcell or traditional IVF (n=20) Primary Endpoints: Blastocyst generation rate: number of&#xD;
      day 5 embryos of &quot;good quality&quot; defined as 2BB or greater (expansion of embryo 2,3,4,5 or 6&#xD;
      and inner cell mass and outer cell mass grades of A or B) or higher using the Gardner Grading&#xD;
      System divided by the number of eggs incubated Patient acceptability of INVOcell and&#xD;
      intravaginal culture.&#xD;
&#xD;
      Secondary Endpoints: Live birth rate: number of cycles with a live birth divided by the&#xD;
      number of cycles with embryo transfers.&#xD;
&#xD;
      Clinical pregnancy rate: number of cycles with fetal heartbeat at week 7 divided by the&#xD;
      number of cycles with embryo transfers.&#xD;
&#xD;
      Fertilization rate: Number of embryos obtained after incubation divided by the number of&#xD;
      oocytes placed in the device.&#xD;
&#xD;
      Embryo transfer rate: Number of cycles initiated divided by the number of cycles with embryo&#xD;
      transfers Miscarriage rate: Number of miscarriages divided by the number of cycles with&#xD;
      embryo transfers Multiple rate: Number cycles with twins or triplets divided by the number of&#xD;
      cycles with embryo transfers Miscarriage rate per clinical pregnancy: Number of miscarriages&#xD;
      divided by the number of cycles with clinical pregnancy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blastocyst Quality</measure>
    <time_frame>Measures assessed following 5 days incubation, approximately 17 days following randomization</time_frame>
    <description>Blastocyst generation rate: number of day 5 embryos of &quot;good quality&quot; defined as 2BB or greater (expansion of embryo 2,3,4,5 or 6 and inner cell mass and outer cell mass grades of A or B) or higher using the Gardner Grading System divided by the number of eggs incubated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Acceptability</measure>
    <time_frame>Measures assessed at first followup visit following embryo transfer, approximately 9 weeks post randomization</time_frame>
    <description>Patient acceptability of INVOcell and intravaginal culture using a 12 point subjective and quantitative questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live Birth Rate</measure>
    <time_frame>Measures assessed 9 months post embryo transfer, approximately 9 months and two weeks following randomization</time_frame>
    <description>Live birth rate: number of cycles with a live birth divided by the number of cycles with embryo transfers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy Rate</measure>
    <time_frame>Measures assessed approximately 16 days following embryo transfer, approximately 4 weeks following randomization.</time_frame>
    <description>Clinical pregnancy rate: number of cycles with fetal heartbeat at week 7 divided by the number of cycles with embryo transfers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization Rate</measure>
    <time_frame>Measures assessed following 5 days post incubation, approximately 2 and 1/2 weeks post randomization.</time_frame>
    <description>Fertilization rate: Number of embryos obtained after incubation divided by the number of oocytes placed in the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo Transfer Rate</measure>
    <time_frame>Measures assessed following 5 days incubation, approximately 2 and 1/2 weeks following randomization.</time_frame>
    <description>Embryo transfer rate: Number of cycles initiated divided by the number of cycles with embryo transfers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage Rate</measure>
    <time_frame>Measures assessed following embryo transfer and a maximum of 9 months gestation.</time_frame>
    <description>Miscarriage rate: Number of miscarriages divided by the number of cycles with embryo transfers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Rate</measure>
    <time_frame>Measures assessed 9 months after the last subject received an embryo transfer, once all live birth data is known for each embryo.</time_frame>
    <description>Multiple rate: Number cycles with twins or triplets divided by the number of cycles with embryo transfers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Medical Device: INVOcell Culture Device</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>5 day oocyte incubation using INVOcell Culture Device within the vaginal cavity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical Device: IVF Incubator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 day oocyte incubation using traditional IVF incubation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>INVOcell Culture Device</intervention_name>
    <description>INVOcell is a vaginal culture device</description>
    <arm_group_label>Medical Device: INVOcell Culture Device</arm_group_label>
    <other_name>INVOcell, INVOcell Culture Device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IVF Incubation</intervention_name>
    <description>IVF Incubator</description>
    <arm_group_label>Medical Device: IVF Incubator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Couples who will participate to the study will be pre selected for the following major&#xD;
        indications:&#xD;
&#xD;
        Women diagnosed with:&#xD;
&#xD;
          -  Tubal factor&#xD;
&#xD;
          -  Endometriosis (type I to II)&#xD;
&#xD;
          -  Ovulatory dysfunction (slight)&#xD;
&#xD;
          -  Multiple female factors (&lt;2)&#xD;
&#xD;
        Males with slight male factor&#xD;
&#xD;
        Couples with:&#xD;
&#xD;
          -  Unknown factor&#xD;
&#xD;
          -  Multiple factors, from female and male origin (&lt;2)&#xD;
&#xD;
          -  Other rare factors not excluded by the inclusion/exclusion criteria (e.g. cervical&#xD;
             mucus immune factor not treatable by IUI)&#xD;
&#xD;
        The pre-selected couples will be included in the study only if they fulfill the more&#xD;
        specific inclusion and exclusion criteria below.&#xD;
&#xD;
        Couples may be included in the study only if they have been informed about the study and&#xD;
        have given their written consent.&#xD;
&#xD;
        Infertile couple with failure to conceive a recognized pregnancy after one year (or 12&#xD;
        menstrual cycles) of unprotected intercourse IVF has been determined by the physician to be&#xD;
        their next treatment&#xD;
&#xD;
        Women included in the study should:&#xD;
&#xD;
          -  Be between the age of 18 and 38 (up to 38th birthday at the time of the enrollment).&#xD;
&#xD;
          -  Have had a normal gynecological examination and Pap smear in the last 12 months.&#xD;
&#xD;
          -  Have a normal follicle stimulating hormone (&lt;10 mIU/mL) and E2 (&lt;250 pmol/L) on Day 3,&#xD;
             determined in the past 12 months&#xD;
&#xD;
          -  Have an anti-mullerian hormone &gt;1 or &lt;3 ng/mL&#xD;
&#xD;
          -  Have had a normal baseline pelvic ultrasound examination in the past 12 months&#xD;
&#xD;
          -  Have a normal uterine cavity as assessed in the past year by hysterosalpingogram,&#xD;
             sonohysterography or hysteroscopy. Prior tubal ligation is acceptable.&#xD;
&#xD;
          -  Have had negative cervical tests for G.C and Chlamydia in the past 12 months. Have&#xD;
             male partner with a normal semen analysis with a total number of &gt; 15 million total&#xD;
             motile spermatozoa with normal morphology or borderline normal morphology (&gt; 3% with&#xD;
             the strict criteria) and a progression rating of &gt;2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Women to be excluded from this study are those who have:&#xD;
&#xD;
          -  Inability to read and speak English fluently&#xD;
&#xD;
          -  A history of recurrent vaginitis&#xD;
&#xD;
          -  A history of toxic shock syndrome&#xD;
&#xD;
          -  Known allergies to plastic, human serum proteins or gentamicin&#xD;
&#xD;
          -  Had pelvic surgery within the past 8 weeks, excluding diagnostic laparoscopy&#xD;
&#xD;
          -  Pelvic inflammatory disease (PID) within the past 3 months and were treated with&#xD;
             antibiotics&#xD;
&#xD;
          -  Severe endometriosis (stage III-IV) or endometriomas (past or present)&#xD;
&#xD;
          -  Clinical signs of vaginal infection&#xD;
&#xD;
          -  Significant abnormalities of the vaginal cavity&#xD;
&#xD;
          -  Sub mucus or intramural fibroids (&gt;1 cm diameter)&#xD;
&#xD;
          -  Hydrosalpinx&#xD;
&#xD;
          -  Chronic illness, e.g. autoimmune disease, diabetes&#xD;
&#xD;
          -  BMI &gt;36&#xD;
&#xD;
          -  Donor oocytes, donor sperm&#xD;
&#xD;
          -  antral follicle count &lt; 6 or &gt; 20&#xD;
&#xD;
          -  Anti-Mullerian Hormone &lt;1 or &gt;3&#xD;
&#xD;
          -  Previously responded poorly to ovarian stimulation and polycystic ovary patients&#xD;
&#xD;
          -  High responder to ovarian stimulation&#xD;
&#xD;
          -  Cervical stenosis, as demonstrated by failed mock embryo transfer&#xD;
&#xD;
          -  Cannot tolerate a speculum examination&#xD;
&#xD;
          -  Unwilling or unable to wear a retention system (diaphragm) during the 5 days of&#xD;
             incubation.&#xD;
&#xD;
        &gt; 2 previously failed IVF (neg Î²hCG)&#xD;
&#xD;
          -  Previously failed fertilization of all oocytes previous IVF cycle&#xD;
&#xD;
          -  Smoke or abuse drugs and alcohol&#xD;
&#xD;
          -  Poor understanding of the procedure&#xD;
&#xD;
          -  Partner with vasectomy reversal&#xD;
&#xD;
          -  Partner with difficulty in producing sperm specimen&#xD;
&#xD;
          -  Partner with uro-genital infection. Sperm culture will be performed if the partner&#xD;
             shows or has shown some symptoms of uro-genital infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>C.A.R.E.</name>
      <address>
        <city>Beford</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ranoux C, Aubriot FX, Dubuisson JB, Cardone V, Foulot H, Poirot C, Chevallier O. A new in vitro fertilization technique: intravaginal culture. Fertil Steril. 1988 Apr;49(4):654-7.</citation>
    <PMID>3350160</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <last_update_submitted>January 18, 2016</last_update_submitted>
  <last_update_submitted_qc>January 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intravaginal culture</keyword>
  <keyword>in vitro fertilization</keyword>
  <keyword>blastocyst</keyword>
  <keyword>pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

